24059-89-0

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-CYANO-3-METHOXYPYRIDINE is used as a key intermediate in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
2-CYANO-3-METHOXYPYRIDINE serves as a valuable building block in organic synthesis, enabling the creation of a wide range of chemical products through its reactivity and structural features.
Used as an Antifungal Agent:
2-CYANO-3-METHOXYPYRIDINE is utilized for its antifungal properties, potentially offering a solution to combat fungal infections in various settings.
Used as an Antiviral Agent:
2-CYANO-3-METHOXYPYRIDINE has been studied for its antiviral activity, suggesting its potential use in treating viral diseases and infections.
Used in Agrochemical Production:
2-CYANO-3-METHOXYPYRIDINE finds applications in the production of agrochemicals, contributing to the development of pesticides and other agricultural chemicals to protect crops and enhance yields.
Used in Pharmaceutical Intermediates:
As a pharmaceutical intermediate, 2-CYANO-3-METHOXYPYRIDINE plays a crucial role in the synthesis of various active pharmaceutical ingredients, facilitating the advancement of medicinal chemistry.

InChI:InChI=1/C7H6N2O/c1-10-7-3-2-4-9-6(7)5-8/h2-4H,1H3

Upstream product

• 14906-61-7 3-methoxypyridine N-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 2402-97-3 3-bromopyridine N-oxide 
• 24100-18-3 2-bromo-3-methoxypyridine 
• 124-41-4 sodium methylate 
• 38180-46-0 3-chloro-2-cyanopyridine 
• 773837-37-9 sodium cyanide 
• 67-56-1 methanol 
• 557-21-1 zinc(II) cyanide 
• 97509-75-6 3-fluoropicolinonitrile 
• 93560-55-5 2-iodo-3-methoxy-pyridine 
• 51315-07-2 3-nitropyridine-2-carbonitrile 
• 34851-41-7 tetrabutyl ammonium methoxide 

Downstream Products

• 379227-03-9 1-(3-methoxypyridin-2-yl)ethanone 
• 573762-39-7 5-amino-3-methoxypyridine-2-carbonitrile 
• 36145-03-6 [2,2'-bipyridine]-3,3'-diol 

Relevant academic research and scientific papers

Development of a scaleable synthesis of NDT 9533750, a key intermediate to a series of novel subtype preferring GABAA partial agonists

A scaleable route to 6-chloro-4-[2-(3-fluoropyridin-2-yl)-imidazol-1- ylmethyl]-5-propyl-pyrimidine (NDT 9S33750), a key intermediate to a series of novel subtype preferring GABAA partial agonists, is described in which various scaleup issues were addressed to provide an efficient and robust route for the preparation of kilogram quantities of the compound.

METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER

This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat pancreatic cancer.

RAD51 Inhibitors

This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

A Bifunctional Reagent Designed for the Mild, Nucleophilic Functionalization of Pyridines

Herein is reported the design and application of a reagent for the direct functionalization of pyridines. These reactions occur under mild conditions and exhibit broad functional group tolerance, enabling the late-stage functionalization of drug-like molecules. The reagent can be easily prepared on large scale from inexpensive reagents, and reacts in the title reaction with acetonitrile, sodium chloride, and sodium methanesulfonate as the sole byproducts. Although this Communication focuses primarily on reactions with cyanide as nucleophile, preliminary experiments with other nucleophiles foreshadow the broad reaching synthetic utility of this approach.

CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer and conditions involving mitochondrial dysfunction. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1,R2,R3,R4,R5,R6,R7,R8 and R9 are as defined herein.

Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy

Nrf2 activators represent a good drug target for designing agents to treat diseases associated with oxidative stress. Building upon previous work, we designed and prepared a series of heterocyclic chalcone-based Nrf2 activators with reduced lipophilicity

FUNCTIONALIZED HETROARYL ENONES EXHIBITING NRF2 ACTIVATION AND THEIR METHOD OF USE

Pharmaceutical compositions are disclosed, which include functionalized hetroaryl enones and are useful for treating or preventing a disease, disorder or condition associated with an NRF2-regulated pathway and/or which involves oxidative stress.

Copper-catalyzed cyanation of heterocycle carbon-hydrogen bonds

A method for regioselective cyanation of heterocycles has been developed. A number of aromatic heterocycles as well as azulene can be cyanated in reasonable to good yields by using a copper cyanide catalyst and an iodine oxidant.

Tetrabutylammonium salt induced denitration of nitropyridines: Synthesis of fluoro-, hydroxy-, and methoxypyridines

(Chemical Equation Presented) An efficient method for the synthesis of fluoropyridines via the fluorodenitration reaction is reported. The reaction is mediated by tetrabutylammonium fluoride (TBAF) under mild conditions without undue regard to the presence of water. The fluorodenitration is general for 2- or 4-nitro-substituted pyridines, while 3-nitropyridines require attendant electron-withdrawing groups for the reaction to proceed efficiently. Nitropyridines also undergo hydroxy- and methoxydenitration under mild conditions in the presence of the corresponding tetrabutylammonium species.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.